Amgen has completed the BLA submission to the FDA for panitumumab for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy, including oxaliplatin and/or irinotecan containing regimens. The rolling BLA submission was initiated in December 2005. Amgen and Abgenix’s data from a randomized Phase III trial of 463 patients showed that those who received the drug every two weeks showed a 46% decrease in tumor progression rate versus those who received...